Paper Details

  1. Home
  2. Paper Details

Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study.

Author: FujishimaHiroshi, GomesPaul, HasunumaTomoko, HollanderDavid A, KawakitaTetsuya, SekiyaTakuro

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Once-daily Alcaftadine 0.25% is effective and safe for preventing signs and symptoms of Japanese cedar-pollen allergic conjunctivitis. This study found that Alcaftadine 0.25% was superior to vehicle for relief of ocular itching and conjunctival hyperemia at 16 hours and was non-inferior to olopatadine at 4 hours.
Paper Details　
Original Abstract of the Article :
<b>Purpose</b>: This study evaluated the efficacy and safety of once-daily Alcaftadine 0.25% (AGN-229666) for prevention of signs and symptoms of Japanese cedar-pollen allergic conjunctivitis.<b>Methods</b>: This was a single-center, placebo-, and comparator-controlled study using the Ora-CAC&#174;...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/09273948.2020.1760309

データ提供：米国国立医学図書館（NLM）

Alcaftadine: A New Hope for Allergic Conjunctivitis

This research explores the effectiveness of alcaftadine 0.25% for preventing allergic conjunctivitis, a common condition that causes itchy and irritated eyes. It's like seeking relief from the burning sands of the desert, finding a refreshing oasis that provides much-needed comfort. This study evaluates the efficacy and safety of alcaftadine, providing valuable insights into its potential as a treatment option for allergic conjunctivitis.

The researchers conducted a randomized controlled trial comparing alcaftadine to placebo and a comparator drug, olopatadine. They found that alcaftadine was effective in relieving ocular itching and conjunctival hyperemia, demonstrating its potential as a safe and effective treatment option. It's like discovering a hidden spring in the desert, offering a sustainable source of relief for those suffering from itchy eyes.

A New Option for Relief

This study highlights the potential of alcaftadine as a safe and effective treatment for allergic conjunctivitis, providing a new option for those seeking relief from itchy and irritated eyes. It's like finding a new source of fresh water in the desert, offering a sustainable solution for those seeking comfort and relief.

Navigating the Desert of Eye Allergies

This research provides valuable insights into the treatment of allergic conjunctivitis, helping us navigate the challenges of this common condition. It's like finding a new oasis in the desert, offering a safe haven from the burning sands of allergic irritation.

Dr.Camel's Conclusion

This study is a beacon of hope for those struggling with allergic conjunctivitis. Alcaftadine offers a promising new option for relief, providing a refreshing oasis in the desert of eye allergies. By providing effective treatment options, we can help individuals navigate the discomfort of this common condition and restore their eye health and well-being.

Date :
  1. Date Completed 2022-02-25
  2. Date Revised 2022-02-25
Further Info :

Pubmed ID

32501774

DOI: Digital Object Identifier

10.1080/09273948.2020.1760309

Related Literature

Article Analysis
・Effects of alcaftadine ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.